NO20061662L - Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament - Google Patents

Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament

Info

Publication number
NO20061662L
NO20061662L NO20061662A NO20061662A NO20061662L NO 20061662 L NO20061662 L NO 20061662L NO 20061662 A NO20061662 A NO 20061662A NO 20061662 A NO20061662 A NO 20061662A NO 20061662 L NO20061662 L NO 20061662L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
receptor antagonist
steroidal anti
inflammatory drug
active ingredient
Prior art date
Application number
NO20061662A
Other languages
English (en)
Norwegian (no)
Inventor
Nigel Boughton-Smith
Simon Cruwys
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20061662L publication Critical patent/NO20061662L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20061662A 2003-09-18 2006-04-11 Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament NO20061662L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302488A SE0302488D0 (sv) 2003-09-18 2003-09-18 New combination
PCT/SE2004/001334 WO2005025571A1 (fr) 2003-09-18 2004-09-15 Composition pharmaceutique comprenant un antagoniste du recepteur p2x7 et un medicament anti-inflammatoire non steroidien.

Publications (1)

Publication Number Publication Date
NO20061662L true NO20061662L (no) 2006-04-11

Family

ID=29212490

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061662A NO20061662L (no) 2003-09-18 2006-04-11 Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament

Country Status (20)

Country Link
US (1) US20070082930A1 (fr)
EP (1) EP1663224A1 (fr)
JP (1) JP2007505900A (fr)
KR (1) KR20060086942A (fr)
CN (1) CN1859911A (fr)
AR (1) AR045783A1 (fr)
AU (1) AU2004271886B2 (fr)
BR (1) BRPI0414558A (fr)
CA (1) CA2538416A1 (fr)
IL (1) IL173913A0 (fr)
IS (1) IS8396A (fr)
MX (1) MXPA06002722A (fr)
NO (1) NO20061662L (fr)
NZ (1) NZ545964A (fr)
RU (1) RU2338556C2 (fr)
SE (1) SE0302488D0 (fr)
TW (1) TW200526199A (fr)
UY (1) UY28517A1 (fr)
WO (1) WO2005025571A1 (fr)
ZA (1) ZA200602260B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
US20070032465A1 (en) * 2003-05-29 2007-02-08 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha
WO2004105796A1 (fr) * 2003-05-29 2004-12-09 Astrazeneca Ab Nouvelle combinaison
US20070010497A1 (en) * 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
WO2007008157A1 (fr) * 2005-07-11 2007-01-18 Astrazeneca Ab Nouvelle combinaison 2
US20080207577A1 (en) * 2005-07-11 2008-08-28 Astrazeneca Ab Combination I
WO2007098086A2 (fr) * 2006-02-17 2007-08-30 Avalon Pharmaceuticals Dérivés d'hydroxypipéridine et leurs utilisations
WO2009074518A1 (fr) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinaisons formées de modulateurs au prolinamide du récepteur p2x7 et d'autres agents thérapeutiques
GB0724258D0 (en) * 2007-12-12 2008-01-30 Glaxo Group Ltd Novel combinations
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
AU2010328203B2 (en) 2009-12-08 2014-05-15 The United States Government As Represented By The Department Of Veterans Affairs Improved methods and compositions for vein harvest and autografting
CA2792258A1 (fr) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Compositions de cellules dendritiques induites et utilisations associees
US20140322193A1 (en) * 2011-12-02 2014-10-30 Michael Kaleko Therapies for Disorders of the Cornea and Conjunctiva
RU2702898C2 (ru) * 2014-09-10 2019-10-14 Гск Консьюмер Хелткер С.А. Композиции диклофенака натрия для местного применения

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US5399564A (en) * 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
TR199802385T2 (xx) * 1996-05-20 1999-04-21 Darwin Discovery Limited TNF inhibit�rleri ve FDE-IV inhibit�rleri olarak kinolin karboksamidler.
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
CZ20013608A3 (cs) * 1999-04-09 2002-05-15 Astrazeneca Ab Adamantanové deriváty
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
CN1434713A (zh) * 1999-12-22 2003-08-06 法马西亚公司 环加氧酶－2抑制剂的缓释制剂
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
HUP0400390A2 (hu) * 2001-07-02 2004-09-28 Akzo Nobel N.V. Tetrahidrokinolin-származékok és ezeket tartalmazó gyógyszerkészítmények
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (fr) * 2001-11-12 2003-05-22 Pfizer Products Inc. Derives de n-adamantylalkyle benzamide en tant qu'antagonistes du recepteur p2x7
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004105796A1 (fr) * 2003-05-29 2004-12-09 Astrazeneca Ab Nouvelle combinaison
US20070032465A1 (en) * 2003-05-29 2007-02-08 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha
US20070010497A1 (en) * 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
IL173913A0 (en) 2006-07-05
JP2007505900A (ja) 2007-03-15
AR045783A1 (es) 2005-11-16
IS8396A (is) 2006-04-03
SE0302488D0 (sv) 2003-09-18
US20070082930A1 (en) 2007-04-12
NZ545964A (en) 2009-09-25
KR20060086942A (ko) 2006-08-01
UY28517A1 (es) 2005-04-29
EP1663224A1 (fr) 2006-06-07
RU2006112423A (ru) 2007-11-10
AU2004271886A1 (en) 2005-03-24
ZA200602260B (en) 2007-07-25
WO2005025571A1 (fr) 2005-03-24
BRPI0414558A (pt) 2006-11-07
RU2338556C2 (ru) 2008-11-20
CA2538416A1 (fr) 2005-03-24
AU2004271886B2 (en) 2008-03-20
CN1859911A (zh) 2006-11-08
TW200526199A (en) 2005-08-16
MXPA06002722A (es) 2006-06-06

Similar Documents

Publication Publication Date Title
NO20061662L (no) Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament
CY1122336T1 (el) Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις
NO20073259L (no) Nye 4-arylaminopyndondenvater som MEK inhibrtorer av hyperproliferende lidelser
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
UY26926A1 (es) Derivados de la quinolina y quinazolina
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
DK2298743T3 (da) p38-Kinaseinhibitorer på grundlag af en 5-leddet heterocyclisk ring
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
NO20074109L (no) Intravenose formuleringer av PDE-5 inhibitorer
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
UY27462A1 (es) Derivados de quinolina
JP2006508953A5 (fr)
WO2005011586A3 (fr) Traitement et prevention d'accidents cardiovasculaires
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
CY1106927T1 (el) Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
WO2006074265A3 (fr) Therapie combinee et compositions pharmaceutiques utilisees dans le traitement des troubles inflammatoires
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
NO20071806L (no) Tabletter med steds- og tidsregulert gastrointestinal frigivelse av aktiv bestanddel.
MXPA05012705A (es) Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
WO2006100213A8 (fr) Composition comprenant un antagoniste du recepteur du thromboxane et un inhibiteur de la thromboxane synthase et un inhibiteur de cox-2 combines
NO20056218L (no) Substituerte pyrrolderivater og anvendelse derav som HMF-CoA reduktase-inhibitorer
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application